https://orcid.org/0000-0002-0568-6625
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
abstract
Introduction
The new coronavirus pandemic has appreciably impacted morbidity and mortality, as well as having an economic impact worldwide. New vaccines are a potential way forward to reduce transmission rates and subsequent infection. In Brazil, vaccines are being distributed via the public sector; however, in the future, they will be available in the private market. Information about consumers’ willingness to pay (WTP) for a hypothetical vaccine against SARS CoV-2 can help future price setting discussions.
Methods
A cross-sectional study was conducted with consumers in the five regions of Brazil regarding the WTP for a hypothetical vaccine against SARS CoV-2 with a 50% efficacy.
Results
A total of 1402 individuals over 18 years of age who declared not having COVID-19 at the time of the survey were interviewed. The acceptability for this hypothetical vaccine was 80.7%. In addition, the amount of WTP by Brazilian consumers for a hypothetical SARS CoV-2 vaccine was estimated at US$ 22.18(120.00 BRL).
Conclusion
This study can contribute to decision-making to inform potential pricing for a hypothetical SARS CoV-2 vaccine.
Article Highlight
The COVID-19 pandemic represented, until this moment, 14,122,795 confirmed cases and 381,475 deaths between March of 2020 and April of 2021, highlighting the Brazil as country with the most cases and deaths in Latin America, according to WHO.
In Brazil, COVID-19 healthcare is available free of charge throughout the national territory by Public Health System, and a safe and effective vaccine for COVID-19 prevention represents an important strategy for the control of the disease.
This study estimated the WTP of Brazilian consumers for a hypothetical SARS-CoV-2 vaccine through an analysis of contingent valuation.
50% of the interviewees were willing to pay US$ 22.18 (120.00 BRL) for a hypothetical vaccine against SARS-CoV-2 infection.
The study can contribute for discussions about the pricing of COVID vaccines to be adopted into the market in Brazil.
Declaration of interest
LPG received financial support by FAPEMIG. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contributions
IPDG, TTRS, EAR, LPG, AAGJ and CMR undertook the study and EAR conducted the analysis, with BG contributing to the literature review. AAGJ, BG, CMR, JAT and FAA subsequently revised the draft and produced the final and revised manuscripts. All authors approved the final and revised manuscripts. All authors also agree to be accountable for all aspects of the work.